INT4313

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 1975
Last Reported 2009
Negated 0
Speculated 1
Reported most in Abstract
Documents 8
Total Number 11
Disease Relevance 0.38
Pain Relevance 2.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (PIF1) helicase activity (PIF1) DNA binding (PIF1)
Anatomy Link Frequency
pituitary 2
neurons 1
brains 1
neural 1
PIF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
noradrenaline 11 99.76 Very High Very High Very High
Dopamine 7 99.52 Very High Very High Very High
Opioid 4 98.84 Very High Very High Very High
antagonist 8 98.76 Very High Very High Very High
Morphine 14 98.44 Very High Very High Very High
Deafferentation 28 97.46 Very High Very High Very High
anesthesia 7 75.04 Quite High
narcan 4 66.32 Quite High
agonist 4 55.84 Quite High
Clonidine 1 43.28 Quite Low
Disease Link Frequency Relevance Heat
Stress 4 82.44 Quite High
Coma 18 57.76 Quite High
Unconsciousness 24 5.00 Very Low Very Low Very Low
Pain 15 5.00 Very Low Very Low Very Low
Convulsion 12 5.00 Very Low Very Low Very Low
Cognitive Disorder 9 5.00 Very Low Very Low Very Low
Persistent Vegetative State 6 5.00 Very Low Very Low Very Low
Sleep Disorders 6 5.00 Very Low Very Low Very Low
Paralysis 6 5.00 Very Low Very Low Very Low
Akinetic Mutism 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
VC, FVC, FEV1 and PIF decreased in all patients.
Localization (decreased) of PIF
1) Confidence 0.39 Published 2009 Journal Anestezjol Intens Ter Section Body Doc Link 20201340 Disease Relevance 0 Pain Relevance 0
However, the increase of serum prolactin following reserpine was in all probability caused by inhibition of PIF secretion.
Localization (secretion) of PIF
2) Confidence 0.22 Published 1975 Journal Endocrinology Section Abstract Doc Link 1109897 Disease Relevance 0.07 Pain Relevance 0.33
Since both drugs inhibited prolactin release from pituitaries in vitro, the decrease of prolactin levels following L-dopa in vivo might have been caused not only by stimulation of PIF release but also at least partly by the direct effect of the drug on the pituitary.
Localization (release) of PIF in pituitary
3) Confidence 0.22 Published 1975 Journal Endocrinology Section Abstract Doc Link 1109897 Disease Relevance 0.08 Pain Relevance 0.34
It is concluded that hypothalamic deafferentation prevents ether-induced release of prolactin and that the "low" levels of the deafferented animals are probably due to a tonic release of prolactin-inhibiting factor (PIF) from the isolated island.
Localization (release) of PIF associated with deafferentation
4) Confidence 0.21 Published 1975 Journal Endocrinology Section Abstract Doc Link 1109897 Disease Relevance 0.06 Pain Relevance 0.22
It is though that this continuous release of PIF might be maintained by persisting autonomous activity of the adrenergic, presumably dopaminergic, neurons contained in the isolated island.
Localization (release) of PIF in neurons
5) Confidence 0.17 Published 1975 Journal Endocrinology Section Abstract Doc Link 1109897 Disease Relevance 0.05 Pain Relevance 0.18
Prolactin release is controlled by prolactin-release inhibiting factor (PIF), possibly dopamine, and an unidentified putative hypothalamic prolactin-releasing factor (PRF).
Localization (release) of PIF associated with dopamine
6) Confidence 0.09 Published 1988 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 2907416 Disease Relevance 0 Pain Relevance 0.46
Morphine and related opioids may indirectly stimulate prolactin release by inhibiting PIF release and (or) by stimulating putative PRF release.
Localization (release) of PIF associated with opioid and morphine
7) Confidence 0.09 Published 1988 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 2907416 Disease Relevance 0 Pain Relevance 0.68
The aims of this study were to use primary cultures of ovine pituitary cells to examine the receptor subtypes that mediate the inhibitory effect of noradrenaline on prolactin secretion and, by using receptor antagonists in vivo, determine whether noradrenaline acts as a prolactin release-inhibiting factor (PIF).
Spec (whether) Localization (release) of PIF in pituitary associated with antagonist and noradrenaline
8) Confidence 0.09 Published 2000 Journal J. Neuroendocrinol. Section Abstract Doc Link 10718926 Disease Relevance 0 Pain Relevance 0.63
The information integration for subset S, or ?
Localization (subset) of integration
9) Confidence 0.04 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC543470 Disease Relevance 0 Pain Relevance 0
are apparently not easy to achieve, however, correspondingly high levels of experience are probably available to only a few kinds of systems, primarily complex brains containing the right type of architecture for maximizing functional specialization and integration.
Localization (specialization) of integration in brains
10) Confidence 0.04 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC543470 Disease Relevance 0.11 Pain Relevance 0
As shown by computer simulations, systems of neural elements whose connectivity jointly satisfies the requirements for functional specialization and for functional integration are well suited to integrating information.
Localization (specialization) of integration in neural
11) Confidence 0.04 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC543470 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox